Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612079 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1958526 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31566285 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11298926 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2077715 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5838793 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL45206 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22612080 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27414 | 0.95 | — | — | |
| Water SCHEMBL8961471 | 0.91 | NPC1 (0.34) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023151113-A1 | SELECTIVE HISTONE DEACETYLASE 8 DEGRADER, PREPARATION METHOD AND APPLICATION THEREOF IN ANTI-TUMOR ACTIVITY | 深圳大学 | 2023-08-17 | — | — | WO | claimed |
| US-9435045-B2 | Reaction products of guanidine compounds or salts thereof, polyepoxides and polyhalogens | ROHM AND HAAS ELECTRONIC MATERIALS LLC | 2016-09-06 | — | — | US | claimed |
| US-9404193-B1 | Reaction products of guanidine compounds or salts thereof, polyepoxides and polyhalogens | ROHM AND HAAS ELECTRONIC MATERIALS LLC | 2016-08-02 | — | — | US | claimed |
| US-9403762-B2 | Reaction products of guanidine compounds or salts thereof, polyepoxides and polyhalogens | ROHM AND HAAS ELECTRONIC MATERIALS LLC | 2016-08-02 | — | — | US | claimed |
| US-20160208400-A1 | REACTION PRODUCTS OF GUANIDINE COMPOUNDS OR SALTS THEREOF, POLYEPOXIDES AND POLYHALOGENS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2016-07-21 | — | — | US | claimed |
| US-20160201209-A1 | REACTION PRODUCTS OF GUANIDINE COMPOUNDS OR SALTS THEREOF, POLYEPOXIDES AND POLYHALOGENS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2016-07-14 | — | — | US | claimed |
| CN-120051461-A | VHH antibody conjugates | 雅博得乐医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025076236-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-117730107-A | Phosphonium-based polymers and copolymers as additives for chemical mechanical planarization slurries | 弗萨姆材料美国有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023151113-A1 | SELECTIVE HISTONE DEACETYLASE 8 DEGRADER, PREPARATION METHOD AND APPLICATION THEREOF IN ANTI-TUMOR ACTIVITY | 深圳大学 | 2023-08-17 | — | — | WO | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2021105497-A1 | SMALL-MOLECULE NADPH OXIDASE 2 INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2021-06-03 | — | — | WO | disclosed |
| EP-2933282-A1 | REACTION PRODUCTS OF HETEROCYCLIC NITROGEN COMPOUNDS, POLYEPOXIDES AND POLYHALOGENS | Rohm and Haas Electronic Materials LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2886538-A1 | Reaction products of guanidine compounds or salts thereof, polyepoxides and polyhalogens | Rohm and Haas Electronic Materials LLC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150136611-A1 | REACTION PRODUCTS OF GUANIDINE COMPOUNDS OR SALTS THEREOF, POLYEPOXIDES AND POLYHALOGENS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2015-05-21 | — | — | US | disclosed |
| US-20110139626-A1 | ELECTROLYTIC COPPER COATING, METHOD OF MANUFACTURING THE SAME, AND COPPER ELECTROLYTE FOR MANUFACTURING ELECTROLYTIC COPPER COATING | FURUKAWA ELECTRIC CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2302103-A1 | ELECTROLYTIC COPPER COATING AND METHOD OF MANUFACTURE THEREFOR, AND COPPER ELECTROLYTE FOR MANUFACTURING ELECTROLYTIC COPPER COATINGS | The Furukawa Electric Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-7153844-B2 | Estrogen-linked platinum (II) complexes as anticancer agents | Berube, Gervais (CA) | 2006-12-26 | — | — | US | disclosed |
| US-20040006051-A1 | Estrogen-linked platinum (II) complexes as anticancer agents | GERVAIS BERUBE (CA) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | NPC1 3709/4885MAPT 946/4885RAB9A 4189/4885 |
| US-20150136611-A1 | REACTION PRODUCTS OF GUANIDINE COMPOUNDS OR SALTS THEREOF, POLYEPOXIDES AND POLYHALOGENS | POLR1C, UNG, PARG | NPC1 4761/4885MAPT 2073/4885RAB9A 3295/4885 |
| US-20040006051-A1 | Estrogen-linked platinum (II) complexes as anticancer agents | ESR2, PGR, ESR1 | NPC1 3557/4885MAPT 4639/4885RAB9A 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.